Clinical TrialJul 6, 2026, 07:07 AM
Can-Fite Completes Phase 3 Psoriasis Patient Enrollment for Interim Analysis
AI Summary
Can-Fite BioPharma Ltd. announced the completion of patient enrollment for the interim analysis of its pivotal Phase 3 study evaluating Piclidenoson for moderate-to-severe plaque psoriasis. The study has enrolled 247 patients, and the interim analysis will proceed under a protocol agreed upon with both the FDA and EMA. Results from this analysis are anticipated in Q4 2026 or Q1 2027, marking a significant milestone for the oral drug candidate.
Key Highlights
- Completed enrollment of 247 patients for the interim analysis of the pivotal Phase 3 study for Piclidenoson.
- The study evaluates Piclidenoson for the treatment of moderate-to-severe plaque psoriasis.
- Interim analysis will be conducted under a protocol agreed with both the U.S. FDA and European EMA.
- Results from the interim analysis are expected during Q4 2026/Q1 2027.
- Piclidenoson is a first-in-class oral A3 adenosine receptor agonist with a favorable safety profile.
Price Impact
More from CANF